Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drug Development To See “Vast Improvements” In Speed – Thompson

Executive Summary

HHS Secretary Thompson vows to make "vast improvements" in expediting oncology drug development using the FDA/National Cancer Institute Interagency Oncology Task Force

You may also be interested in...



ClinicalTrials.gov Noncompliance Remains An FDA Concern

The pharmaceutical industry's failure to list cancer trial information on ClinicalTrials.gov remains a concern to FDA, Oncology Drug Products Division Director Richard Pazdur, MD, said May 12

ClinicalTrials.gov Noncompliance Remains An FDA Concern

The pharmaceutical industry's failure to list cancer trial information on ClinicalTrials.gov remains a concern to FDA, Oncology Drug Products Division Director Richard Pazdur, MD, said May 12

CMS/NCI Will Test Model For Evidence-Based Reimbursement

A collaboration between the National Cancer Institute and the Centers for Medicare & Medicaid Services will examine cancer therapies as a model for evidence-based reimbursement, NCI Director Andrew von Eschenbach, MD, told the Milken Institute Global Conference in Los Angeles April 26-27

Related Content

UsernamePublicRestriction

Register

PS043559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel